Experimental
Chemo Combo for Colon Cancer Disappoints. Again a targeted
(this time) antibody-based drug (mab) fails!
Adding the
drug cetuximab (brand name Erbitux) to standard chemotherapy after surgery for
stage 3 colon cancer did not improve disease-free survival in patients, a new
study concludes.
Surprised?
No. It
was expected. Which product fails next?
No comments:
Post a Comment